CN Patent

CN116507338A — NF-κB介导的疾病的治疗

Assigned to Reveragen Biopharma Inc · Expires 2023-07-28 · 3y expired

What this patent protects

本披露提供了治疗或减轻年龄在1天至18岁之间的人患者的肌营养不良症状的方法，这些方法包括向有需要的该人患者施用治疗有效量的伐莫洛酮和/或其盐。

USPTO Abstract

本披露提供了治疗或减轻年龄在1天至18岁之间的人患者的肌营养不良症状的方法，这些方法包括向有需要的该人患者施用治疗有效量的伐莫洛酮和/或其盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN116507338A
Jurisdiction
CN
Classification
—
Expires
2023-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Reveragen Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.